Hematology Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Department of Thoracic Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
In Vivo. 2019 Sep-Oct;33(5):1531-1538. doi: 10.21873/invivo.11633.
Pericardial synovial sarcomas (PSS) are very rare tumors, with dismal prognosis and limited data. We describe the clinical features and identify prognostic factors of primary PSS.
We describe the case of a 56-year-old male patient with PSS managed by the multidisciplinary team of thoracic oncology. The therapeutic plan comprised surgery, chemotherapy, stereotactic radiosurgery and targeted therapy, with excellent results.
Data from 37 cases reported in English during the past 20 years were gathered and analyzed. PSS was found to occur at a mean age of 36±17.082 (range=13-67) years. Survival analysis was performed on 20 cases with follow-up of at least 6 months.
Only complete resection of the tumor seems to be an independent prognostic factor. To our knowledge, this is the first report on the safety and effectivity of pazopanib in PSS and may provide guidance for similar cases in the future.
心包滑膜肉瘤（PSS）是一种非常罕见的肿瘤，预后较差，相关数据有限。我们描述了原发性 PSS 的临床特征，并确定了其预后因素。
我们描述了一位 56 岁男性患者的病例，该患者由胸肿瘤科多学科团队进行治疗。治疗计划包括手术、化疗、立体定向放射外科和靶向治疗，取得了良好的效果。
收集并分析了过去 20 年中以英文报告的 37 例病例的数据。PSS 的平均发病年龄为 36±17.082 岁（范围为 13-67 岁）。对至少随访 6 个月的 20 例病例进行生存分析。
似乎只有完全切除肿瘤才是独立的预后因素。据我们所知，这是首例关于帕唑帕尼治疗 PSS 的安全性和有效性的报告，可为今后类似病例提供指导。
